The Effect of Coenzyme Q10 Therapy in Parkinson Disease Could Be Symptomatic

Randomized, Double-blind, Placebo-Controlled Trial on Symptomatic Effects of Coenzyme Q10 in Parkinson Disease

“…We found no significant differences in the frequency and quality of adverse events in the CoQ 10 group compared with the placebo control group. These data are in line with previous studies using various formulations of CoQ 10 in patients with PD 12,14,23 and other neurological and nonneurological conditions. 9,25,28 To our knowledge, this is the first trial systematically investigating the safety and symptomatic efficacy of high doses of CoQ 10 in patients with PD.…”

Randomized, Double-blind, Placebo-Controlled Trial on Symptomatic Effects of Coenzyme Q10 in Parkinson Disease

“…We found no significant differences in the frequency and quality of adverse events in the CoQ 10 group compared with the placebo control group. These data are in line with previous studies using various formulations of CoQ 10 in patients with PD 12,14,23 and other neurological and nonneurological conditions. 9,25,28 To our knowledge, this is the first trial systematically investigating the safety and symptomatic efficacy of high doses of CoQ 10 in patients with PD.…”

Safety Assessment of PureSorb-QTM40 in Healthy Subjects and Serum Coenzyme Q10 Level in Excessive Dosing

“…Needless to say, the results can not be simply compared due to the different conditions; however, this is almost the same result as previously reported, that the serum CoQ10 absorption rate for P40 tablets was faster than that of the soft-gel capsules, although a different dose of CoQ10 was administered in the single dose study (9). In addition, in an other study, it is reported that when 1,500 mg/d of CoQ10 was administered repeatedly for 3 mo to Parkinson's disease patients (11), the mean increase of serum CoQ10 level for the study was about 5.3 g/mL. Compared with this study, the above-mentioned result in the present study was about 1.5-fold higher.…”

Coenzyme Q10: Clinical Applications beyond Cardiovascular Diseases

“…High doses were reported also by Horstink et al, in an open label trial on a limited number of patients ( n = 12) who received 1000 mg/day of CoQ 10 for three months and then 1500 mg/day of CoQ 10 for other three months. At the end of the trial, lower but statistically significant benefits on motor performance in patients who received 1500 mg/day vs. placebo were recorded [ 75 ]. In order to assess tolerability of high doses, in 2004, Shults et al, performed an open label study on 17 patients who received growing CoQ 10 dosages from 1200 mg to 3000 mg/day over 8 weeks.…”

Randomized, Double-blind, Placebo-Controlled Trial on Symptomatic Effects of Coenzyme Q10 in Parkinson Disease

“…We found no significant differences in the frequency and quality of adverse events in the CoQ 10 group compared with the placebo control group. These data are in line with previous studies using various formulations of CoQ 10 in patients with PD 12,14,23 and other neurological and nonneurological conditions. 9,25,28 To our knowledge, this is the first trial systematically investigating the safety and symptomatic efficacy of high doses of CoQ 10 in patients with PD.…”

Safety Assessment of PureSorb-QTM40 in Healthy Subjects and Serum Coenzyme Q10 Level in Excessive Dosing

“…Needless to say, the results can not be simply compared due to the different conditions; however, this is almost the same result as previously reported, that the serum CoQ10 absorption rate for P40 tablets was faster than that of the soft-gel capsules, although a different dose of CoQ10 was administered in the single dose study (9). In addition, in an other study, it is reported that when 1,500 mg/d of CoQ10 was administered repeatedly for 3 mo to Parkinson's disease patients (11), the mean increase of serum CoQ10 level for the study was about 5.3 g/mL. Compared with this study, the above-mentioned result in the present study was about 1.5-fold higher.…”

Coenzyme Q10: Clinical Applications beyond Cardiovascular Diseases

“…High doses were reported also by Horstink et al, in an open label trial on a limited number of patients ( n = 12) who received 1000 mg/day of CoQ 10 for three months and then 1500 mg/day of CoQ 10 for other three months. At the end of the trial, lower but statistically significant benefits on motor performance in patients who received 1500 mg/day vs. placebo were recorded [ 75 ]. In order to assess tolerability of high doses, in 2004, Shults et al, performed an open label study on 17 patients who received growing CoQ 10 dosages from 1200 mg to 3000 mg/day over 8 weeks.…”

Randomized, Double-blind, Placebo-Controlled Trial on Symptomatic Effects of Coenzyme Q10 in Parkinson Disease

“…We found no significant differences in the frequency and quality of adverse events in the CoQ 10 group compared with the placebo control group. These data are in line with previous studies using various formulations of CoQ 10 in patients with PD 12,14,23 and other neurological and nonneurological conditions. 9,25,28 To our knowledge, this is the first trial systematically investigating the safety and symptomatic efficacy of high doses of CoQ 10 in patients with PD.…”

Safety Assessment of PureSorb-QTM40 in Healthy Subjects and Serum Coenzyme Q10 Level in Excessive Dosing

“…Needless to say, the results can not be simply compared due to the different conditions; however, this is almost the same result as previously reported, that the serum CoQ10 absorption rate for P40 tablets was faster than that of the soft-gel capsules, although a different dose of CoQ10 was administered in the single dose study (9). In addition, in an other study, it is reported that when 1,500 mg/d of CoQ10 was administered repeatedly for 3 mo to Parkinson's disease patients (11), the mean increase of serum CoQ10 level for the study was about 5.3 g/mL. Compared with this study, the above-mentioned result in the present study was about 1.5-fold higher.…”

Coenzyme Q10: Clinical Applications beyond Cardiovascular Diseases

“…High doses were reported also by Horstink et al, in an open label trial on a limited number of patients ( n = 12) who received 1000 mg/day of CoQ 10 for three months and then 1500 mg/day of CoQ 10 for other three months. At the end of the trial, lower but statistically significant benefits on motor performance in patients who received 1500 mg/day vs. placebo were recorded [ 75 ]. In order to assess tolerability of high doses, in 2004, Shults et al, performed an open label study on 17 patients who received growing CoQ 10 dosages from 1200 mg to 3000 mg/day over 8 weeks.…”